Geneoscopy, a leader in the development of groundbreaking diagnostics for gastrointestinal health, is pleased to welcome Don Hardison to its Board of Directors. With more than four decades of executive experience in the diagnostics, biotechnology and life sciences industries, both at emerging and Fortune 500 companies, Mr. Hardison is sure to bring a wealth of knowledge and expertise to the team.
Mr. Hardison has held a number of influential positions in the healthcare industry, including President and CEO of Biotheranostics until its acquisition by Hologic in February 2021, President, CEO, and Director at Good Start Genetics, and President and CEO of Exact Sciences, where he was instrumental in the company’s initial public offering. In addition, he has served in senior leadership roles at companies such as Labcorp.
We are thrilled to welcome Don to our Board at this crucial moment in Geneoscopy’s development! Don brings a wealth of expertise and acumen, having served as an accomplished executive in our industry. His guidance will be instrumental in our aim of delivering innovative, noninvasive diagnostics for gastrointestinal health to providers and patients who need it most. Andrew Barnell, Chief Executive Officer and Geneoscopy’s co-founder, is delighted to have Don join the Board.
Mr. Hardison has recently been appointed to Geneoscopy’s Board of Directors, where he will help guide the company’s commercialization of its innovative noninvasive, stool-based, at-home screening test designed to detect colorectal cancer and advanced adenomas in average-risk individuals. This past January, Geneoscopy submitted a Premarket Approval (PMA) application to the U.S. Food and Drug Administration after the successful completion of the CRC-PREVENT trial. With two years of experience as a strategic advisor, Mr. Hardison is well-placed to take on this new role and help Geneoscopy realize its ambitions of providing a revolutionary colorectal cancer screening test.
I’m thrilled to join the board of Geneoscopy at such an exciting moment in their development. The recent submission of their PMA – the first regulatory approval application – is a major milestone and I’m eager to support their commercial strategy as they continue to make progress. Having served as an advisor to them for the last two years, I’ve been impressed by their success in executing their strategy and am proud to be a part of their journey.
About Geneoscopy Inc.
Geneoscopy Inc. is revolutionizing the way we look at gastrointestinal health. With its patented stool-derived eukaryotic RNA (seRNA) biomarker platform, the life sciences company is developing diagnostic tests that enable patients and providers to gain greater insights into gastrointestinal conditions. Beyond colorectal cancer screening, Geneoscopy’s innovative diagnostics are being used to diagnose, select treatments, and monitor therapy in numerous disease areas, in collaboration with renowned universities and biopharmaceuticals. With Geneoscopy, taking control of your gastrointestinal health is just a few steps away.